Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.78 |
| ▸ | MEN1 | O00255 | 3/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | TP53 | P04637 | 1/20 | 0.78 |
| ▸ | HPGD | P15428 | 1/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.78 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | FLT3 | P36888 | 1/20 | 0.76 |
| ▸ | ACHE | P22303 | 1/20 | 0.75 |
| ▸ | MAOB | P27338 | 1/20 | 0.75 |
| ▸ | AR | P10275 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19086305 | 1.00 | ABCG2 (0.78) | ABCG2CYP3A4MEN1KMT2AMAPT | |
| SCHEMBL28678909 | 0.90 | MAOB (0.71) | ABCG2CYP3A4MEN1KMT2AMAPT | |
| SCHEMBL29416645 | 0.90 | MAOB (0.71) | ABCG2CYP3A4MEN1KMT2AMAPT | |
| SCHEMBL30383806 | 0.87 | ABCG2 (1.00) | ABCG2CYP3A4MEN1KMT2AMAPT | |
| SCHEMBL633469 | 0.87 | ABCG2 (1.00) | ABCG2CYP3A4MEN1KMT2AMAPT | |
| SCHEMBL25217986 | 0.87 | ABCG2 (1.00) | ABCG2CYP3A4MEN1KMT2AMAPT | |
| SCHEMBL25223496 | 0.87 | CYP3A4 (0.67) | ABCG2CYP3A4MEN1KMT2AMAPT | |
| SCHEMBL633470 | 0.87 | ABCG2 (1.00) | ABCG2CYP3A4MEN1KMT2AMAPT | |
| SCHEMBL25223485 | 0.87 | CYP3A4 (0.66) | ABCG2CYP3A4MEN1KMT2AMAPT | |
| SCHEMBL25238512 | 0.87 | ACHE (0.81) | ABCG2CYP3A4MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3188721-B1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LTD (IE) | 2019-06-12 | — | — | EP | claimed |
| US-20170216222-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-08-03 | — | — | US | claimed |
| EP-3188721-A1 | HUMAN THERAPEUTIC AGENTS | Ions Pharmaceutical S.À.R.L. (LU) | 2017-07-12 | — | — | EP | claimed |
| WO-2023090908-A1 | NOVEL FLAVONOID DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE | 고려대학교 세종산학협력단 | 2023-05-25 | — | — | WO | disclosed |
| EP-3275465-B1 | THERAPEUTIC COMPOSITIONS COMPRISING A COMBINATION OF A HARMINE AND ISOVANILLIN COMPONENT | ANKH LIFE SCIENCES LTD (IE) | 2020-05-06 | — | — | EP | disclosed |
| EP-3188721-B1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LTD (IE) | 2019-06-12 | — | — | EP | disclosed |
| EP-3275465-A1 | THERAPEUTIC COMPOSITIONS COMPRISING A COMBINATION OF A HARMINE AND ISOVANILLIN COMPONENT | Ions Pharmaceutical S.À.R.L. (LU) | 2018-01-31 | — | — | EP | disclosed |
| WO-2017132135-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216222-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | ABCG2 629/4885CYP3A4 1368/4885MEN1 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.